FDA Announces Bystolic Shortage

Share this content:
FDA Announces Bystolic Shortage
FDA Announces Bystolic Shortage

The Food and Drug Administration (FDA) announced that Bystolic (nebivolol; Forest Laboratories) 20 mg is currently in shortage.

Bystolic 20-mg tablets in 30- and 90-count bottles are currently unavailable and backordered due to a manufacturing delay based upon commercial stability data. The estimated duration of the backorder is 4 to 6 months. However, Bystolic 10-mg tablets are available to cover the demand for the 20-mg tablets.

Bystolic is a cardioselective beta-blocker indicated for the treatment of hypertension in adults aged at least 18 years. In addition to the 10-mg tablets, it is also available as 2.5-mg and 5-mg tablets.

For more information call (888) 463-6332 or visit FDA.gov.

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters



CME Focus